Dr. Martens plc (DRMTY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Dr. Martens plc (DRMTY) trades at $1.91. Dr. Martens plc designs, develops, and distributes footwear globally, operating under the iconic Dr. Martens brand. Market cap: $915.38M, Sector: Consumer cyclical.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for DRMTY: DRMTY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DRMTY against Consumer Cyclical peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DRMTY: 1/1 perspectives are bearish.
How is this calculated? →Dr. Martens plc (DRMTY) Consumer Business Overview
Dr. Martens plc, a global footwear brand established in 1945, designs, markets, and distributes a range of footwear and accessories, including its signature originals and fusion styles, across Europe, the Americas, and Asia-Pacific, holding a significant position in the apparel and footwear industry.
What Is the Investment Thesis for DRMTY?
Dr. Martens plc presents a compelling investment case based on its strong brand heritage and global presence. With a P/E ratio of 29.7 and a dividend yield of 4.11%, the company offers a blend of growth and income potential. The company's gross margin of 61.1% indicates strong pricing power and efficient cost management. Growth catalysts include expansion in key international markets and continued innovation in product design. However, investors should be aware of potential risks such as fluctuations in consumer spending and competition from other footwear brands. The company's beta of 0.20 suggests relatively low volatility compared to the broader market.
Based on FMP financials and quantitative analysis
DRMTY Key Highlights
- Market capitalization of $915.38M reflects Dr. Martens' established position in the global footwear market.
- Gross margin of 61.1% demonstrates strong brand pricing power and efficient cost management.
- Dividend yield of 4.11% provides an attractive income stream for investors.
- Beta of 0.20 indicates lower volatility compared to the overall market, potentially offering stability in uncertain economic conditions.
- Presence in Europe, the Middle East, Africa, the Americas, and Asia-Pacific provides a diversified revenue base.
Who Are DRMTY's Competitors?
DRMTY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DMPZF Domino's Pizza Group plc | $2.51 | +2.65% | $957.84M | 48 |
| DPUKY Domino's Pizza Group plc | $4.91 | +3.81% | $936.85M | 45 |
| GRUPF Fnac Darty S.A. | $66.00 | +0.00% | $1.01B | 54 |
| JDWPY J D Wetherspoon plc | $43.79 | -4.80% | $923.14M | 44 |
| JNBYF JNBY Design Limited | $2.09 | +0.00% | $1.10B | 50 |
| DPNEY Daphne International Holdings Limited | $0.98 | +0.00% | $96.95M | 60 |
| ASCCY ASICS Corporation | $29.21 | +5.77% | $20.71B | 60 |
| DPNEF Daphne International Holdings Limited | $0.02 | -56.75% | $34.23M | 56 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DRMTY's Key Strengths?
- Strong brand recognition and heritage
- Iconic and durable designs
- Global distribution network
- High gross margin
What Are DRMTY's Weaknesses?
- Reliance on footwear sales
- Exposure to fashion trends
- Potential for supply chain disruptions
- Limited product diversification
What Could Drive DRMTY Stock Higher?
- Continued expansion in key international markets, particularly in Asia-Pacific, driving revenue growth.
- Product innovation and the introduction of new styles and designs, attracting new customers and maintaining brand relevance.
- Potential strategic partnerships with retailers and distributors, expanding the company's reach and market access.
- Growth in e-commerce sales, driven by investments in digital marketing and enhanced online shopping experience.
What Are the Key Risks for DRMTY?
- Fluctuations in consumer spending, impacting demand for Dr. Martens products.
- Intense competition from other footwear brands, requiring ongoing investment in marketing and product development.
- Changes in fashion trends, potentially impacting the appeal of Dr. Martens' classic designs.
- Supply chain disruptions, affecting the availability of raw materials and finished goods.
- Currency fluctuations, impacting the profitability of international sales.
What Are the Growth Opportunities for DRMTY?
- Expansion in Asia-Pacific: Dr. Martens has a significant opportunity to expand its presence in the Asia-Pacific region, particularly in markets like China and India. The growing middle class and increasing disposable incomes in these countries are driving demand for branded footwear. By investing in localized marketing campaigns and distribution channels, Dr. Martens can capitalize on this growth potential and increase its market share. The Asia-Pacific footwear market is projected to reach multi-billion dollar valuations by 2030.
- E-commerce Growth: The increasing popularity of online shopping presents a significant growth opportunity for Dr. Martens. By enhancing its e-commerce platform and investing in digital marketing, the company can reach a wider customer base and drive online sales. The global e-commerce market is experiencing rapid growth, with online footwear sales projected to increase substantially over the next five years. Dr. Martens can leverage this trend by offering a seamless online shopping experience and personalized customer service.
- Product Innovation: Dr. Martens can drive growth by continuing to innovate and introduce new products that appeal to a broader range of consumers. This includes developing new styles, materials, and technologies that enhance the comfort, durability, and style of its footwear. By staying ahead of fashion trends and catering to evolving consumer preferences, Dr. Martens can maintain its competitive edge and attract new customers. The company can also explore collaborations with designers and influencers to create limited-edition collections that generate excitement and demand.
- Brand Extensions: Dr. Martens can leverage its strong brand equity to expand into new product categories, such as apparel and accessories. This allows the company to diversify its revenue streams and increase its brand presence in the market. By offering a range of complementary products that align with its brand identity, Dr. Martens can create a more comprehensive lifestyle offering for its customers. The global apparel and accessories market is a multi-billion dollar industry, offering significant growth potential for Dr. Martens.
- Strategic Partnerships: Dr. Martens can pursue strategic partnerships with retailers, distributors, and other companies to expand its reach and access new markets. This includes partnering with leading department stores and specialty retailers to increase its distribution network, as well as collaborating with other brands to create co-branded products and marketing campaigns. By leveraging the expertise and resources of its partners, Dr. Martens can accelerate its growth and strengthen its competitive position.
What Opportunities Does DRMTY Have?
- Expansion in emerging markets
- Growth in e-commerce sales
- Product innovation and diversification
- Strategic partnerships
What Threats Does DRMTY Face?
- Intense competition from other footwear brands
- Fluctuations in consumer spending
- Changes in fashion trends
- Economic downturns
What Are DRMTY's Competitive Advantages?
- Strong brand recognition and heritage built over decades.
- Unique and iconic designs that differentiate Dr. Martens from competitors.
- High-quality materials and construction that ensure durability and longevity.
- Global distribution network that provides access to a wide range of markets.
What Does DRMTY Do?
Dr. Martens plc, founded in 1945, is a global footwear brand renowned for its iconic and durable designs. Originating in post-war Germany with Dr. Klaus Maertens' air-cushioned sole innovation, the brand gained popularity in the UK after being licensed to the Griggs family. Initially embraced by workers for their comfort and durability, Dr. Martens boots were later adopted by various subcultures, solidifying their status as a symbol of self-expression and rebellion. Today, Dr. Martens offers a diverse product portfolio, including its classic 'Originals' line, contemporary 'Fusion' styles, children's footwear, casual shoes, and accessories. The company operates across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific region, marketing its products through a combination of owned retail stores, e-commerce platforms, and wholesale partnerships. Dr. Martens continues to evolve while maintaining its core identity, appealing to a broad consumer base seeking quality, style, and individuality.
What Products and Services Does DRMTY Offer?
- Designs and develops a wide range of footwear products.
- Procures raw materials and components for manufacturing.
- Markets and promotes its products through various channels.
- Sells footwear through owned retail stores, e-commerce platforms, and wholesale partners.
- Distributes its products globally across Europe, the Americas, and Asia-Pacific.
- Offers a diverse product portfolio, including originals, fusion styles, kids' footwear, casual options, and accessories.
How Does DRMTY Make Money?
- Designs and develops footwear products under the Dr. Martens brand.
- Manufactures and distributes its products through a global network of owned stores, e-commerce, and wholesale partners.
- Generates revenue through the sale of footwear and accessories to consumers and retailers.
What Industry Does DRMTY Operate In?
Dr. Martens plc operates within the global apparel and footwear industry, a sector characterized by evolving consumer preferences and intense competition. The industry is influenced by factors such as fashion trends, economic conditions, and technological advancements. The global footwear market is projected to reach significant growth in the coming years, driven by increasing demand from emerging markets and the growing popularity of e-commerce. Dr. Martens competes with a range of established and emerging brands, focusing on its unique brand identity and heritage to differentiate itself in the market.
Who Are DRMTY's Key Customers?
- Individuals seeking durable and stylish footwear.
- Fashion-conscious consumers looking for iconic and trendsetting designs.
- Retailers and distributors who sell Dr. Martens products to end consumers.
FY2026 estForward Outlook
Wall Street analysts project Dr. Martens plc revenue of about $769.7M for fiscal 2026, with EPS near $0.00. The estimate reflects 5 contributing analysts.
F-Score 6/9Financial Health
Dr. Martens plc's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 6.17 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 7%Key Financial Metrics
Return on equity for Dr. Martens plc stands at 6.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.7%, showing how much profit it generates from its asset base. DRMTY trades at a trailing price-to-earnings ratio of 29.73, below the Consumer Cyclical sector average of ~39x. Its free cash flow yield is 17.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.61 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.6%, the inverse of the P/E and a quick read on earnings relative to price.
Dr. Martens plc (DRMTY) Valuation Context
Valued at $915.38M, DRMTY is classified as a small-cap stock.
Company Profile
Dr. Martens plc operates in the Apparel - Footwear & Accessories industry within the Consumer Cyclical sector. It is headquartered in London, GB. The company is led by CEO Onyeije Ogueri Nwokorie. DRMTY has traded publicly since 2022.
DRMTY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Dr. Martens' brand still resonates strongly with younger generations, suggesting sustained demand.
- Recent collaborations and limited-edition releases have generated significant buzz, indicating successful marketing strategies.
- The company's focus on direct-to-consumer channels seems to be paying off, potentially improving profit margins.
- Despite broader economic concerns, Dr. Martens' iconic status might provide some resilience during downturns.
Bear Case
- Community sentiment indicates some concern about the brand potentially becoming overexposed and losing its counter-cultural appeal.
- Increased competition in the footwear market, particularly from brands offering similar styles at lower price points, could erode market share.
- Recent supply chain disruptions and rising raw material costs may put pressure on profitability.
- There's a growing perception that the company needs to innovate beyond its classic designs to maintain long-term relevance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
DRMTY Latest News
-
Dr. Martens CEO Is Latest Shoe Chief Buying Company Shares to Shore Up Confidence
Yahoo! Finance: DRMTY News · Jun 16, 2026
DRMTY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DRMTY.
Price Targets
Wall Street price target analysis for DRMTY.
DRMTY MoonshotScore
What does this score mean?
The MoonshotScore rates DRMTY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Onyeije Ogueri Nwokorie
CEO
Onyeije Ogueri Nwokorie serves as the CEO of Dr. Martens plc, leading the company's global operations and strategic direction. His professional background includes experience in the consumer goods and retail sectors. He has held various leadership positions, demonstrating expertise in brand management, marketing, and international expansion. His experience positions him to guide Dr. Martens through its next phase of growth and innovation, leveraging the brand's iconic status and global reach.
Track Record: Since joining Dr. Martens, Onyeije Ogueri Nwokorie has focused on strengthening the brand's digital presence and expanding its reach in key international markets. He has overseen the launch of new product lines and collaborations, driving revenue growth and enhancing the company's brand image. His strategic decisions have contributed to Dr. Martens' continued success in the competitive footwear market.
Dr. Martens plc ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. DRMTY is an ADR that allows U.S. investors to invest in Dr. Martens plc without directly dealing with foreign stock exchanges. Each DRMTY ADR represents a specific number of Dr. Martens plc shares traded on its home market.
- Home Market Ticker: London Stock Exchange (LSE), United Kingdom
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: DRMT
DRMTY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier typically do not meet the minimum financial standards or reporting requirements of exchanges like the NYSE or NASDAQ. This tier is considered the most speculative and carries the highest risk due to the limited information available and the potential for fraud or manipulation. Investing in companies on the OTC Other tier requires significant due diligence and a high-risk tolerance.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Wider bid-ask spreads
- Potential for price volatility and manipulation
- Higher risk of fraud or misrepresentation
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Be prepared to lose your entire investment.
- Established brand name and history
- Global presence and distribution network
- Positive brand reputation and customer reviews
- Listing as an ADR, suggesting some level of regulatory oversight
- CEO with relevant experience in the consumer goods sector
Common Questions About DRMTY (Consumer Cyclical)
What does Dr. Martens plc do?
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear globally. The company's product segments include originals, fusion, kids, and casual, as well as accessories. It operates under the Dr. Martens brand name, selling through owned retail stores, e-commerce platforms, and wholesale partners. The company's iconic footwear is known for its durability, style, and association with various subcultures, appealing to a broad consumer base seeking quality and individuality.
What do analysts say about DRMTY stock?
Analyst consensus on DRMTY stock is currently mixed, reflecting the company's growth potential and inherent risks. Key valuation metrics, such as the P/E ratio of 29.7, suggest a premium valuation compared to some peers. Growth considerations include the company's expansion in Asia-Pacific and its e-commerce strategy. Investors should carefully evaluate these factors and conduct their own research before making any investment decisions. Analyst ratings and price targets are subject to change based on market conditions and company performance.
What are the main risks for DRMTY?
The main risks for DRMTY include fluctuations in consumer spending, intense competition from other footwear brands, and changes in fashion trends. A decline in consumer confidence or disposable income could negatively impact demand for Dr. Martens products. The company also faces competition from established and emerging footwear brands, requiring ongoing investment in marketing and product development. Additionally, changes in fashion trends could impact the appeal of Dr. Martens' classic designs, requiring the company to adapt and innovate to maintain its market position.
What are the key factors to evaluate for DRMTY?
Evaluate DRMTY on fundamentals, analyst consensus, and risk factors. P/E: 29.7x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does DRMTY data refresh on this page?
DRMTY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DRMTY's recent stock price performance?
Dr. Martens plc (DRMTY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand recognition and heritage. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DRMTY overvalued or undervalued right now?
Dr. Martens plc (DRMTY) trades at 29.7x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DRMTY?
Before investing in Dr. Martens plc (DRMTY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for DRMTY, which may provide additional insights.
- OTC market data may be less reliable than exchange-listed data.